‘‘Roluperidone is an investigational 5-HT2A, sigma2 and α 1A-adrenergic receptor antagonist. The NDA submission included data from phase 3 MIN-101 study, which evaluated the efficacy and safety of roluperidone in 513 adult patients with moderate to severe negative symptoms of schizophrenia. Showed an improvement in negative symptoms (as measured by the Positive and Negative Syndrome Scale PANSS Marder Negative Symptoms Factor Score) in patients receiving roluperidone 64mg compared with placebo.’’
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia | 4 | 375 | August 23, 2022 | |
| Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression | 15 | 786 | November 29, 2019 | |
| Minerva Awaits Verdict for Schizophrenia Drug from FDA | 9 | 366 | February 22, 2024 | |
| Long-term effects of Roluperidone on negative symptoms of schizophrenia - PubMed | 3 | 317 | March 19, 2023 | |
| Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia | 10 | 423 | March 1, 2022 |